Notriptyline for smoking cessation: A review

Nicotine and Tobacco Research

Volumn 7, Issue 4, 2005, Pages 491-500

  Hughes, John R ^a   Stead, Lindsay F ^b   Lancaster, Tim ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIHISTAMINIC AGENT; CLONIDINE; DOPAMINE; DOXEPIN; IMIPRAMINE; MOCLOBEMIDE; NICOTINE; NORADRENALIN; NORTRIPTYLINE; PLACEBO; SEDATIVE AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADRENERGIC ACTIVITY; BODY WEIGHT DISORDER; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; DATA ANALYSIS; DEPRESSION; DIZZINESS; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; INFORMATION PROCESSING; INFORMATION RETRIEVAL; LETHAL DOSE; LONG TERM CARE; MEDLINE; META ANALYSIS; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOTHERAPY; PSYCINFO; REVIEW; RISK BENEFIT ANALYSIS; SCISEARCH; SEDATION; SIDE EFFECT; SMOKING CESSATION; SOCIAL BELIEF; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; TREMOR; VALIDATION PROCESS; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA; CONTROLLED CLINICAL TRIAL; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; EVIDENCE-BASED MEDICINE; HUMANS; NORTRIPTYLINE; RANDOMIZED CONTROLLED TRIALS; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 27744492646     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1080/14622200500185298     Document Type: Review

References (53)

1. Benowitz, N. L. (1998). Nicotine safety and toxicity. New York: Oxford University Press.
2. Benowitz, N. L., Dempsey, D. A., Goldenberg, R. L., Hughes, J. R., Dolan-Mullen, P., Ogburn, P. L., Oncken, C., Orleans, C. T., Slotkin, T. A., Whiteside, H. P. Jr., & Yaffe, S. (2000). The use of pharmacotherapies for smoking cessation during pregnancy. Tobacco Control, 9(Suppl. 3), iii91-iii94.
3. Benowitz, N. L., & Wilson Peng, M. (2000). Non-nicotine pharmacotherapy for smoking cessation. Mechanisms and prospects. CNS Drugs, 13, 265-285.
4. Berlin, I., Aubin, H. J., Pedarriosse, A. M., Rames, A., & Lancrenon, S. L. G. (2002). Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction, 97, 1347-1354.
5. Berlin, I., Said, S., Spreux-Varoquaux, O., Launay, J. M., Olivares, R., Millet, V., Lecrubier, Y., & Puech, A. J. (1995). Clinical trial and therapeutics. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clinical Pharmacology and Therapeutics, 58, 444-452.
6. Biberman, R., Neumann, R., Katzir, I., & Gerber, Y. (2003). A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction, 98, 1403-1407.
7. Burgess, E. S., Brown, R. A., Kahler, C. W., Niaura, R., Abrams, D. B., Goldstein, M. G., & Miller, I. W. (2002). Patterns of change in depressive symptoms during smoking cessation: Who's at risk for relapse? Journal of Consulting and Clinical Psychology, 70, 356-351.
8. Centers for Disease Control and Prevention. (2004). Cigarette smoking among adults - United States, 2002. Morbidity and Mortality Weekly Report, 53, 427-431.
9. Covey, L. S., Sullivan, M. A., Johnston, J. A., Glassman, A. H., Robinson, M. D., & Adams, D. P. (2000). Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs, 59, 17-31.
10. Cryan, J. F., Gasparini, F., van Heeke, G., & Markou, A. (2003). Non-nicotinic neuropharmacological strategies for nicotine dependence: Beyond bupropion. Drug Discovery Today, 8, 1025-1034.
11. Da Costa, C. L., Younes, R. N., & Cruz Lourenco, M. T. (2002). Stopping smoking: A prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest, 122, 403-408.
12. Dilsaver, S. C. (1994). Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Safety, 10, 103-114.
13. Fiore, M. C., Bailey, W. C., Cohen, S. J., Dorfman, S. F., Gritz, E. R., Heyman, R. B., Holbrook, J., Jaen, C. R., Kottke, T. E., Lando, H. A., Mecklenbur, R., Mullen, P. D., Nett, L. M., Robinson, L., Stitzer, M., Tommasello, A. C., Villejo, L., & Wewers, M. E. (2000). Treating tobacco use and dependence. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service.
14. French, S. A., & Jeffery, R. W. (1995). Weight concerns and smoking: A literature review. Annals of Behavioral Medicine, 17, 234-244.
15. Fryer, J. D., & Lukas, R. J. (1999). Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. Journal of Neurochemistry, 72, 1117-1124.
16. George, T. P., & O'Malley, S. S. (2004). Current pharmacological treatments for nicotine dependence. Trends in Pharmacological Sciences, 25, 42-48.
17. George, T. P., Vessicchio, J. C., Termine, A., Jatlow, P. I., Kosten, T. R., & O'Malley, S. S. (2003). A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biological Psychiatry, 53, 136-143.
18. Glassman, A. H., Schildkraut, J. J., Orsulak, P. J., Cooper, T. B., Kupfer, D. J., Shader, R. I., Davis, J. M., Carroll, B., Perel, J. M., Klerman, G. L., & Greenblatt, D. J. (1985). Tricyclic antidepressants - Blood level measurements and clinical outcome: An APA Task Force report. American Journal of Psychiatry, 142, 155-162.
19. Greenland, S., Satterfield, M. H., & Lanes, S. F. (1998). A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Safety, 18, 297-308.
20. Hall, S. M., Humfleet, G. L., Reus, V. I., Munoz, R. F., & Cullen, J. (2004). Extended nortriptyline and psychological treatment for cigarette smoking. American Journal of Psychiatry, 161, 2100-2107.
21. Hall, S. M., Humfleet, G. L., Reus, V. I., Munoz, R. F., Hartz, D. T., & Griffin, R. M. (2002). Psychological intervention and anti-depressant treatment in smoking cessation. Archives of General Psychiatry, 59, 930-936.
22. Hall, S. M., Reus, V. I., Munoz, R. F., Sees, K. L., Humfleet, G., Hartz, D. T., Frederick, S., & Triffleman, E. (1998). Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Archives of General Psychiatry, 55, 683-690.
23. Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, A., & White, J. D. (2001). Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Annals of Internal Medicine, 135, 423-433.
24. Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analysis. British Medical Journal, 327, 557-560.
25. Hughes, J. R. (1995). Combining behavioral therapy and pharmacotherapy for smoking cessation: An update. In: L. S. Onken, J. D. Blaine, & J. J. Boren (Eds.), Integrating behavior therapies with medication in the treatment of drug dependence (NIDA Research Monograph No. 150; pp. 92-109). Washington, D.C.: National Institute on Drug Abuse.
26. Hughes, J. R. (2001). The evidence for hardening. Is the target hardening? (NCI Smoking and Tobacco Control Monograph). Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
27. Hughes, J. R., & Burns, D. M. (2001). Impact of medications on smoking cessation. In Population based smoking cessation: Proceedings of a conference on what works to influence cessation in the general population (Smoking and Tobacco Control Monograph No. 12; pp. 155-164). Bethesda, MD: National Cancer Institute.
28. Hughes, J. R., Grass, J. A., & Pillitteri, J. L. (2000). Treatment resistant smokers: A pilot study of nicotine nasal spray and inhaler. Journal of Addictive Diseases, 19, 95-100.
29. Hughes, J. R., Keely, J., Niaura, R., Ossip-Klein, D., Richmond, R., & Swan, G. (2003). Measures of abstinence from tobacco in clinical trials: Issues and recommendations. Nicotine & Tobacco Research, 5, 13-25.
30. Hughes, J. R., & Krahn, D. (1985). Blindness and the validity of double-blind drug trials. Journal of Clinical Psychopharmacology, 5, 138-142.
31. Hughes, J. R., Stead, L. F., & Lancaster, T. (2004). Antidepressants for smoking cessation. The Cochrane Database of Systematic Reviews, Issue 4. Oxford, U.K.
32. Jarvis, M. J. (2003). Monitoring cigarette smoking prevalence in Britain in a timely fashion. Addiction, 98, 1569-1574.
33. Karasu, T. B., Docherty, J. P., Gelenberg, A., Kupfer, D. J., Merriam, A. E., & Shadoan, R. (1996). Practice guideline for major depressive disorder in adults. Practice Guidelines, 83-134. Washington, D.C.: American Psychiatric Association.
34. Kenford, S. L., Smith, S. S., Wetter, D. W., Jorenby, D. E., Fiore, M. C., & Baker, T. B. (2002). Predicting relapse back to smoking: Contrasting affective and physical models of dependence. Journal of Consulting and Clinical Psychology, 70, 216-227.
35. Kenny, P. J., & Markou, A. (2001). Neurobiology of the nicotine withdrawal syndrome. Pharmacology, Biochemistry, and Behavior, 70, 531-549.
36. Koob, G. F., & LeMoal, M. (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology, 24, 97-129.
37. Kotlyar, M., Golding, M., Hatsukami, D. K., & Jamerson, B. D. (2001). Effect of nonnicotine pharmacotherapy on smoking behavior. Pharmacotherapy, 21, 1530-1548.
38. Levin, E. D., & Simon, B. B. (1998). Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology, 138, 217-230.
39. Mantel, N., & Haenszel, W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. Journal of National Cancer Institute, 22, 719-748.
40. National Cancer Institute. (2000). Population based smoking cessation: Proceedings of a conference on what works to influence cessation in the general population (Smoking and Tobacco Control Monograph No. 12). Bethesda, MD: National Cancer Institute.
41. National Cancer Institute. (2003). Those who continue to smoke: Is achieving abstinence harder and do we need to change our interventions? (Smoking and Tobacco Control Monograph No. 15; NIH Publication No. 03-5370). Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
42. Nelson, J. C. (2005). Tricyclics and tetracyclics. In: B. J. Sadock & V. A. Sadock (Eds.), Kaplan & Sadock's Comprehensive Textbook of Psychiatry (Vol. II, 8th ed., pp. 2956-2967). New York: Lippincott Williams & Wilkins.
43. Onken, L. S., & Blaine, S. (1998). Potentiating medications with psychotherapy (NIDA Research Monograph Series). Washington, D.C.: U.S. Department of Health and Human Services.
44. Piasecki, T. M., Kenford, S. L., Smith, S. S., Fiore, M. C., & Baker, T. B. (1997). Listening to nicotine: Negative affect and the smoking withdrawal conundrum. Psychological Science, 8, 184-189.
45. Prochazka, A. V., Kick, S., Steinbrunn, C., Miyoshi, T., & Fryer, G. E. (2004). A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Archives of Internal Medicine, 164, 2229-2233.
46. Prochazka, A. V., Weaver, M. J., Keller, R. T., Fryer, G. E., Licari, P. A., & Lofaso, D. (1998). A randomized trial of nortriptyline for smoking cessation. Archives of Internal Medicine, 158, 2035-2039.
47. Raw, M., Anderson, P., Batra, A., Dubois, G., Harrington, P., Hirsch, A., LeHouezec, J., McNeill, A., Milner, D., & Langer, M. P. Z. W. (2002). WHO Europe evidence based recommendations on the treatment of tobacco dependence. Tobacco Control, 11, 44-46.
48. Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2001). Nicotine replacement therapy for smoking cessation (Cochrane Review). The Cochrane Library; Issue 3. Oxford, U.K.: Update Software.
49. U.S. Department of Health and Human Services. (1990). The health benefits of smoking cessation. A report of the surgeon general (DHHS Publication No. CDC90-8416). Rockville, MD: Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Public Health Service.
50. Wagena, E. J., Knipschild, P., & Zeegers, M. P. A. (2005). Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction, 100, 317-326.
51. Warner, K. E., & Burns, D. M. (2003). Hardening and the hard-core smoker: Concepts, evidence, and implications. Nicotine & Tobacco Research, 5, 37-48.
52. West, R., McNeill, A., & Raw, M. (2000). Smoking cessation guidelines for health professionals: An update. Thorax, 55, 987-999.
53. Zevin, S., & Benowitz, N. L. (1999). Drug interactions with tobacco smoking. Clinical Pharmacokinetics, 6, 425-438.